Molecular Pathogenicity of Anti-NMDA Receptor Autoantibody from Patients with First-Episode Psychosis
Julie Jézéquel,Marilyn Lepleux,Rene S Kahn,Jérôme Honnorat,Marion Leboyer,Laurent Groc
DOI: https://doi.org/10.1176/appi.ajp.2017.17091053
IF: 17.7
2018-01-01
American Journal of Psychiatry
Abstract:Back to table of contents Previous article Next article Letters to the EditorFull AccessMolecular Pathogenicity of Anti-NMDA Receptor Autoantibody From Patients With First-Episode PsychosisJulie Jézéquel, Ph.D., Marilyn Lepleux, M.Sc., Rene S. Kahn, M.D., Ph.D., Jérôme Honnorat, M.D., Ph.D., Marion Leboyer, M.D., Ph.D., Laurent Groc, Ph.D.Julie JézéquelSearch for more papers by this author, Ph.D., Marilyn LepleuxSearch for more papers by this author, M.Sc., Rene S. KahnSearch for more papers by this author, M.D., Ph.D., Jérôme HonnoratSearch for more papers by this author, M.D., Ph.D., Marion LeboyerSearch for more papers by this author, M.D., Ph.D., Laurent GrocSearch for more papers by this author, Ph.D.Published Online:1 Apr 2018https://doi.org/10.1176/appi.ajp.2017.17091053AboutSectionsPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack Citations ShareShare onFacebookTwitterLinked InEmail To the Editor: Over the last decade, the detection of autoantibodies against neurotransmitter receptors in patients with neuropsychiatric disorders has raised hopes for a better understanding of the molecular cascades underlying these pathologies and for providing appropriate therapy (1). The link between psychotic disorders and autoimmunity has regained strong support following the discovery of anti–N-methyl-d-aspartate receptor (NMDAR) autoantibody encephalitis, which is associated with psychotic symptoms (2). However, the biological significance of circulating NMDAR autoantibodies from psychotic patients remains poorly understood (3). Indeed, most studies have focused on autoantibody detection assays and prevalence (3) but have hardly addressed whether NMDAR autoantibodies have the potency to alter the localization and, thus, the function of NMDAR, as predicted by the well-established model of NMDAR hypofunction in psychosis (4). Here, we directly addressed this important question by employing the innovative and sensitive single nanoparticle imaging method to examine the functional effect of NMDAR autoantibodies from patients with first-episode psychosis.Schematically, NMDAR autoantibody seropositive patients with first-episode psychosis (4.7%), having minimal or no exposure to antipsychotics, were identified from the OPTIMIZE project (5). To determine whether these patients’ immunoglobulin G antibodies alter the synaptic function of NMDAR in live hippocampal neurons, we used single molecule imaging to localize and track membrane synaptic NMDAR exposed to NMDAR autoantibodies. Indeed, contrary to bulk imaging approaches, the development of single molecule imaging has provided unprecedented information about the dynamic organization of single NMDARs and their pathophysiological regulation.As previously demonstrated (6), membrane NMDARs explore the dendritic and synaptic area, in which they specifically stabilize and contribute to the NMDAR-mediated transmission. When hippocampal neurons were acutely exposed to psychotic patients’ NMDAR autoantibodies, the synaptic NMDARs were clearly destabilized with increased dynamics that contrast with the behavior of receptors exposed to purified immunoglobulin G antibodies from healthy seronegative donors (Figure 1). It is noteworthy that the synaptic disorganization observed with NMDAR autoantibodies in patients with first-episode psychosis resembles the one previously described with NMDAR autoantibodies from anti-NMDA encephalitis patients (7). Thus, because of single molecule imaging, we could determine that NMDAR autoantibodies from patients with first-episode psychosis displaced synaptic NMDAR, leading to an NMDAR hypofunction that constitutes the core hypothesis of psychosis (4). The molecular pathogenicity of NMDAR autoantibodies in patients with first-episode psychosis, which would be relevant in vivo, should prompt clinicians to screen for these autoantibodies because it may open the possibility to use immunotherapy to treat patients with first-episode psychosis who are antibody-positive.FIGURE 1. Single Nanoparticle Tracking of NMDA Receptors at the Surface of Hippocampal Neurons Exposed to Anti-NMDA Receptor Autoantibodies From Patients With First-Episode Psychosisaa Schematic representation of the experimental design used to test the impact of immunoglobulin G antibodies of seropositive patients with first-episode psychosis compared with healthy seronegative donor immunoglobulin G antibodies. Cultured hippocampal neurons were first incubated for 30 minutes with immunoglobulin G antibodies (5 µg/mL), and then synaptic N-methyl-d-aspartate receptor (NMDAR) surface dynamics was measured through single nanoparticle (quantum dot) tracking of GluN2A-NMDAR (enriched in glutamatergic synapses). As shown in the right of panel A, representative single trajectories of surface GluN2A-NMDAR within synapses (gray area; 25-second trajectories) were exposed to immunoglobulin G antibodies from either healthy donors or seropositive patients with first-episode psychosis (scale bar, 500 nm). Panels B and C depict cumulative distributions of and mean synaptic NMDAR instantaneous diffusion coefficients from neurons exposed to healthy seronegative donors or seropositive patients (healthy donors, N=2, individual trajectories, N=1,232; positive patients with first-episode psychosis, N=5, individual trajectories, N=1,365; Mann-Whitney test).***p<0.001.From the Interdisciplinary Institute for Neuroscience, Université de Bordeaux, UMR 5297, Bordeaux, France; CNRS, IINS UMR 5297, Bordeaux, France; the Icahn School of Medicine at Mount Sinai, New York; Institut NeuroMyoGène INSERM U1217/CNRS UMR 5310, Université Claude Bernard Lyon 1, Lyon, France; the Department of Psychiatry, Université Paris Est Créteil, Hôpitaux Universitaires Henri Mondor, AP-HP, DHU PePSY, France; the Translational Psychiatry Laboratory, INSERM U955, France; and FondaMental Foundation, France.Address correspondence to Dr. Groc ([email protected]).Dr. Kahn has received consulting fees from Alkermes, Lundbeck, and Richter. The other authors report no financial relationships with commercial interests.References1 Crisp SJ, Kullmann DM, Vincent A: Autoimmune synaptopathies. Nat Rev Neurosci 2016; 17:103–117Crossref, Medline, Google Scholar2 Dalmau J, Lancaster E, Martinez-Hernandez E, et al.: Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol 2011; 10:63–74Crossref, Medline, Google Scholar3 Pollak TA, Beck K, Irani SR, et al.: Autoantibodies to central nervous system neuronal surface antigens: psychiatric symptoms and psychopharmacological implications. Psychopharmacology (Berl) 2015; 233:1605–1621Crossref, Medline, Google Scholar4 Javitt DC: Glutamate as a therapeutic target in psychiatric disorders. Mol Psychiatry 2004; 9:984–997Crossref, Medline, Google Scholar5 Jézéquel J, Rogemond V, Pollak T, et al.: Cell- and single molecule-based methods to detect anti–N-methyl-d-aspartate receptor autoantibodies in patients with first-episode psychosis from the OPTiMiSE Project. Biol Psychiatry 2017; 82:766–772Crossref, Medline, Google Scholar6 Bard L, Groc L: Glutamate receptor dynamics and protein interaction: lessons from the NMDA receptor. Mol Cell Neurosci 2011; 48:298–307Crossref, Medline, Google Scholar7 Mikasova L, De Rossi P, Bouchet D, et al.: Disrupted surface cross-talk between NMDA and Ephrin-B2 receptors in anti-NMDA encephalitis. Brain 2012; 135:1606–1621Crossref, Medline, Google Scholar FiguresReferencesCited byDetailsCited byNeuronal surface autoantibodies in dementia: a systematic review and meta-analysis18 April 2020 | Journal of Neurology, Vol. 268, No. 8The diverse and complex modes of action of anti-NMDA receptor autoantibodiesNeuropharmacology, Vol. 194Influence of methodological and patient factors on serum NMDAR IgG antibody detection in psychotic disorders: a meta-analysis of cross-sectional and case-control studiesThe Lancet Psychiatry, Vol. 8, No. 2Surface trafficking of neurotransmitter receptors: From cultured neurons to intact brain preparationsNeuropharmacology, Vol. 169B-cells and schizophrenia: A promising link or a finding lost in translation?Brain, Behavior, and Immunity, Vol. 81, Vol. 165Frontiers in Behavioral Neuroscience, Vol. 13Pathogenicity of Antibodies against NMDA Receptor: Molecular Insights into Autoimmune PsychosisTrends in Neurosciences, Vol. 41, No. 8 Volume 175Issue 4 April 01, 2018Pages 382-383 Metrics KeywordsAutoimmunityPsychosisGlutamatePDF download History Accepted 1 December 2017 Published online 1 April 2018 Published in print 1 April 2018